BJ
CTMX icon

BlackRock Japan’s CytomX Therapeutics CTMX Stock Holding History

BlackRock Japan’s Portfolio CTMX Stock Details CTMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		$18K Buy
1,671
+519
+45% +$6.29K ﹤0.01% 1142
2016
Q3 		$18K Buy
1,152
+481
+72% +$5.82K ﹤0.01% 1138
2016
Q2 		$7K Buy
+671
New +$7.65K ﹤0.01% 1310

Other funds holding CTMX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
PI
Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TCM
Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
VMI
VHCP Management II New York $379M AUM 421.62% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

BlackRock Japan's CTMX Position: Q4 2016 in Review

BlackRock Japan increased its CytomX Therapeutics (CTMX) stake by 45% in Q4 2016, buying an estimated $6.29K and bringing the position to 1,671 shares worth $18K. The position accounts for ﹤0.01% of the portfolio, ranked #1142.

BlackRock Japan first reported a position in CTMX in Q2 2016 and has held it in 3 quarters since. 68 funds tracked by Wall St. Rank hold CTMX as of Q4 2016.

  • BlackRock Japan held 1,671 shares of CytomX Therapeutics worth $18K as of Q4 2016.
  • BlackRock Japan bought 519 CytomX Therapeutics shares in Q4 2016, an estimated $6.29K.
  • CytomX Therapeutics made up ﹤0.01% of BlackRock Japan's portfolio in Q4 2016, its #1142 holding.
  • BlackRock Japan first reported a position in CytomX Therapeutics in Q2 2016 and has held it in 3 quarters since.
  • 68 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q4 2016.

Based on BlackRock Japan's 13F filing for Q4 2016, filed 10 Feb 2017.